<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">73641</article-id><article-id pub-id-type="doi">10.7554/eLife.73641</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-258067"><name><surname>Capraz</surname><given-names>Tümay</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254455"><name><surname>Kienzl</surname><given-names>Nikolaus Ferdinand</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8057-3930</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254456"><name><surname>Laurent</surname><given-names>Elisabeth</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5234-5524</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254457"><name><surname>Perthold</surname><given-names>Jan W</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-264780"><name><surname>Föderl-Höbenreich</surname><given-names>Esther</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-264781"><name><surname>Grünwald-Gruber</surname><given-names>Clemens</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254460"><name><surname>Maresch</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254461"><name><surname>Monteil</surname><given-names>Vanessa</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2652-5695</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-264782"><name><surname>Niederhöfer</surname><given-names>Janine</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-254463"><name><surname>Wirnsberger</surname><given-names>Gerald</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-152982"><name><surname>Mirazimi</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57502"><name><surname>Zatloukal</surname><given-names>Kurt</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5299-7218</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-254464"><name><surname>Mach</surname><given-names>Lukas</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-212735"><name><surname>Penninger</surname><given-names>Josef M</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="other" rid="par-9"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-183997"><name><surname>Oostenbrink</surname><given-names>Chris</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4232-2556</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-254452"><name><surname>Stadlmann</surname><given-names>Johannes</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5693-6690</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="cor4">*</xref><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Institute for Molecular Modeling and Simulation</institution>, <institution>University of Natural Resources and Life Sciences</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff2"><institution content-type="dept">nstitute of Plant Biotechnology and Cell Biology, Department of Applied Genetics and Cell Biology</institution>, <institution>University of Natural Resources and Life Sciences</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff3"><institution content-type="dept">BOKU Core Facility Biomolecular and Cellular Analysis</institution>, <institution>University of Natural Resources and Life Sciences</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff4"><institution content-type="dept">Diagnostic and Research Institute of Pathology</institution>, <institution>Medical University of Graz</institution>, <addr-line><named-content content-type="city">Graz</named-content></addr-line>, <country>Austria</country></aff><aff id="aff5"><institution content-type="dept">Institute of Biochemistry, Department of Chemistry</institution>, <institution>University of Natural Resources and Life Sciences</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff6"><institution content-type="dept">Department of Laboratory Medicine</institution>, <institution>Karolinska Institute</institution>, <addr-line><named-content content-type="city">Stockholm</named-content></addr-line>, <country>Sweden</country></aff><aff id="aff7"><institution>Apeiron Biologics AG</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff8"><institution content-type="dept">Institute of Plant Biotechnology and Cell Biology, Department of Applied Genetics and Cell Biology</institution>, <institution>University of Natural Resources and Life Sciences</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff><aff id="aff9"><institution content-type="dept">Institute of Molecular Biotechnology</institution>, <institution>Austrian Academy of Sciences</institution>, <addr-line><named-content content-type="city">Vienna</named-content></addr-line>, <country>Austria</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-43030"><name><surname>Sawyer</surname><given-names>Sara L</given-names></name><role>Reviewing editor</role><aff><institution>University of Colorado Boulder</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>lukas.mach@boku.ac.at</email> (LM);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>josef.penninger@ubc.ca</email> (JP);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>chris.oostenbrink@boku.ac.at</email> (CO);</corresp><corresp id="cor4"><label>*</label>For correspondence: <email>j.stadlmann@boku.ac.at</email> (JS);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>12</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e73641</elocation-id><history><date date-type="received"><day>06</day><month>09</month><year>2021</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Capraz et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Capraz et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-73641-v1.pdf"/><abstract><p>Infection and viral entry of SARS-CoV-2 crucially depends on the binding of its Spike protein to angiotensin converting enzyme 2 (ACE2) presented on host cells. Glycosylation of both proteins is critical for this interaction. Recombinant soluble human ACE2 can neutralize SARS-CoV-2 and is currently undergoing clinical tests for the treatment of COVID-19. We used 3D structural models and molecular dynamics simulations to define the ACE2 N-glycans that critically influence Spike-ACE2 complex formation. Engineering of ACE2 N-glycosylation by site-directed mutagenesis or glycosidase treatment resulted in enhanced binding affinities and improved virus neutralization without notable deleterious effects on the structural stability and catalytic activity of the protein. Importantly, simultaneous removal of all accessible N-glycans from recombinant soluble human ACE2 yields a superior SARS-CoV-2 decoy receptor with promise as effective treatment for COVID-19 patients.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>W1224-B09</award-id><principal-award-recipient><name><surname>Kienzl</surname><given-names>Nikolaus Ferdinand</given-names></name><name><surname>Maresch</surname><given-names>Daniel</given-names></name><name><surname>Mach</surname><given-names>Lukas</given-names></name><name><surname>Oostenbrink</surname><given-names>Chris</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001821</institution-id><institution>Vienna Science and Technology Fund</institution></institution-wrap></funding-source><award-id>COV20-015</award-id><principal-award-recipient><name><surname>Capraz</surname><given-names>Tümay</given-names></name><name><surname>Oostenbrink</surname><given-names>Chris</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Innovative Medicines Initiative 2 Joint Undertaking</institution></institution-wrap></funding-source><award-id>101005026</award-id><principal-award-recipient><name><surname>Monteil</surname><given-names>Vanessa</given-names></name><name><surname>Mirazimi</surname><given-names>Ali</given-names></name><name><surname>Penninger</surname><given-names>Josef M</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>DOC fellowship of the Academy of Sciences</institution></institution-wrap></funding-source><award-id>24987</award-id><principal-award-recipient><name><surname>Perthold</surname><given-names>Jan W</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>T. von Zastrow foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Penninger</surname><given-names>Josef M</given-names></name><name><surname>Stadlmann</surname><given-names>Johannes</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>Z271-B19</award-id><principal-award-recipient><name><surname>Penninger</surname><given-names>Josef M</given-names></name><name><surname>Stadlmann</surname><given-names>Johannes</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001804</institution-id><institution>Canada Research Chairs</institution></institution-wrap></funding-source><award-id>F18-0133</award-id><principal-award-recipient><name><surname>Penninger</surname><given-names>Josef M</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>F20-02343</award-id><principal-award-recipient><name><surname>Penninger</surname><given-names>Josef M</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>F20-02015</award-id><principal-award-recipient><name><surname>Penninger</surname><given-names>Josef M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Janine Niederhöfer, employee of Apeiron Biologics. Apeiron holds a patent on the use of ACE2 for the treatment of lung, heart, or kidney injury and applied for a patent to treat COVID-19 with rshACE2..</p></fn><fn fn-type="conflict" id="conf3"><p>Gerald Wirnsberger, employee of Apeiron Biologics. Apeiron holds a patent on the use of ACE2 for the treatment of lung, heart, or kidney injury and applied for a patent to treat COVID-19 with rshACE2..</p></fn><fn fn-type="conflict" id="conf4"><p>Josef M Penninger, declares a conflict of interest as a founder, supervisory board member, and shareholder of Apeiron Biologics. Apeiron holds a patent on the use of ACE2 for the treatment of lung, heart, or kidney injury and applied for a patent to treat COVID-19 with rshACE2..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Molecular models and simulation trajectories are available through the BioExcel COVID-19 Molecular Structure and Therapeutics Hub (https://covid.bioexcel.eu/simulations/).</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Oostenbrink Lab</collab></person-group><year iso-8601-date="2020">2020</year><source>Blocking SARS-CoV-2 Spike protein binding to human ACE2 receptor</source><ext-link ext-link-type="uri" xlink:href="https://covid.molssi.org//targets/#blocking-sars-cov-2-spike-protein-binding-to-human-ace2-receptor">https://covid.molssi.org//targets/#blocking-sars-cov-2-spike-protein-binding-to-human-ace2-receptor</ext-link><comment>covid.bioexcel.eu/simulations/</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-73641-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>